Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone. My name is Abigail, and I will be your conference operator today. At this time, I would like to welcome you to the Cura Oncology's Q4 and FY 2025 financial results earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, and if you have joined via the webinar, please use the raise hand icon, which can be found at the bottom of your webinar application. To allow everybody the opportunity to participate, we ask that you please limit yourself to one question and then re-enter the queue for any follow-ups. At this time, I would like to turn the call over to Greg Mann, SVP of Investor Relations and Corporate Affairs of Cura Oncology. Please go ahead. Thank you, Abigail. Good morning and welcome to Cura Oncology's fourth quarter 2025 conference call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer, Brian Powell, Chief Commercial Officer, Dr. Molly Leone, Chief Medical Officer, and Tom Doyle, Senior Vice President, Finance and Accounting. We remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected results. Please refer to Cura's filings with the SEC, which are available from the SEC or on the Cura Oncology website, for information concerning risk factors that could affect the company. With that, I'll turn the call over to Troy. Thank you, Greg, and good morning, everyone. 2025 was a defining year for Cura, marked by FDA approval of ComSifty and initiation of a successfu...